Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Gro...
- Autores
- Rapoport, Bernardo L.; Shannon, Vickie R.; Cooksley, Tim; Johnson, Douglas B.; Anderson, Lindsay; Blidner, Ada Gabriela; Tintinger, Gregory R.; Anderson, Ronald
- Año de publicación
- 2021
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, with agents such as nivolumab, pembrolizumab, and cemiplimab targeting programmed cell death protein-1 (PD-1) and durvalumab, avelumab, and atezolizumab targeting PD-ligand 1 (PD-L1). Ipilimumab targets cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). These inhibitors have shown remarkable efficacy in melanoma, lung cancer, urothelial cancer, and a variety of solid tumors, either as single agents or in combination with other anticancer modalities. Additional indications are continuing to evolve. Checkpoint inhibitors are associated with less toxicity when compared to chemotherapy. These agents enhance the antitumor immune response and produce side- effects known as immune-related adverse events (irAEs). Although the incidence of immune checkpoint inhibitor pneumonitis (ICI-Pneumonitis) is relatively low, this complication is likely to cause the delay or cessation of immunotherapy and, in severe cases, may be associated with treatment-related mortality. The primary mechanism of ICI-Pneumonitis remains unclear, but it is believed to be associated with the immune dysregulation caused by ICIs. The development of irAEs may be related to increased T cell activity against cross-antigens expressed in tumor and normal tissues. Treatment with ICIs is associated with an increased number of activated alveolar T cells and reduced activity of the anti-inflammatory Treg phenotype, leading to dysregulation of T cell activity. This review discusses the pathogenesis of alveolar pneumonitis and the incidence, diagnosis, and clinical management of pulmonary toxicity, as well as the pulmonary complications of ICIs, either as monotherapy or in combination with other anticancer modalities, such as thoracic radiotherapy.
Fil: Rapoport, Bernardo L.. University of Pretoria. Faculty of Health Sciences; Sudáfrica. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. The Medical Oncology Centre of Rosebank; Sudáfrica
Fil: Shannon, Vickie R.. University of Texas; Estados Unidos
Fil: Cooksley, Tim. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. University of Manchester; Reino Unido
Fil: Johnson, Douglas B.. Vanderbilt University; Estados Unidos
Fil: Anderson, Lindsay. University of Pretoria. Faculty of Health Sciences; Sudáfrica
Fil: Blidner, Ada Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Tintinger, Gregory R.. University of Pretoria. Faculty of Health Sciences; Sudáfrica
Fil: Anderson, Ronald. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. University of Pretoria. Faculty of Health Sciences; Sudáfrica - Materia
-
ANTI-CTLA-4 ANTIBODIES
ANTI-PDL-1 MONOCLONAL ANTIBODIES
IMMUNE CHECKPOINT INHIBITORS
IMMUNE RELATED ADVERSE EFFECTS
PNEUMONITIS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/163188
Ver los metadatos del registro completo
id |
CONICETDig_b04596928d6c3d7b9fa87c9c194ab3b7 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/163188 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in CancerRapoport, Bernardo L.Shannon, Vickie R.Cooksley, TimJohnson, Douglas B.Anderson, LindsayBlidner, Ada GabrielaTintinger, Gregory R.Anderson, RonaldANTI-CTLA-4 ANTIBODIESANTI-PDL-1 MONOCLONAL ANTIBODIESIMMUNE CHECKPOINT INHIBITORSIMMUNE RELATED ADVERSE EFFECTSPNEUMONITIShttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3https://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, with agents such as nivolumab, pembrolizumab, and cemiplimab targeting programmed cell death protein-1 (PD-1) and durvalumab, avelumab, and atezolizumab targeting PD-ligand 1 (PD-L1). Ipilimumab targets cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). These inhibitors have shown remarkable efficacy in melanoma, lung cancer, urothelial cancer, and a variety of solid tumors, either as single agents or in combination with other anticancer modalities. Additional indications are continuing to evolve. Checkpoint inhibitors are associated with less toxicity when compared to chemotherapy. These agents enhance the antitumor immune response and produce side- effects known as immune-related adverse events (irAEs). Although the incidence of immune checkpoint inhibitor pneumonitis (ICI-Pneumonitis) is relatively low, this complication is likely to cause the delay or cessation of immunotherapy and, in severe cases, may be associated with treatment-related mortality. The primary mechanism of ICI-Pneumonitis remains unclear, but it is believed to be associated with the immune dysregulation caused by ICIs. The development of irAEs may be related to increased T cell activity against cross-antigens expressed in tumor and normal tissues. Treatment with ICIs is associated with an increased number of activated alveolar T cells and reduced activity of the anti-inflammatory Treg phenotype, leading to dysregulation of T cell activity. This review discusses the pathogenesis of alveolar pneumonitis and the incidence, diagnosis, and clinical management of pulmonary toxicity, as well as the pulmonary complications of ICIs, either as monotherapy or in combination with other anticancer modalities, such as thoracic radiotherapy.Fil: Rapoport, Bernardo L.. University of Pretoria. Faculty of Health Sciences; Sudáfrica. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. The Medical Oncology Centre of Rosebank; SudáfricaFil: Shannon, Vickie R.. University of Texas; Estados UnidosFil: Cooksley, Tim. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. University of Manchester; Reino UnidoFil: Johnson, Douglas B.. Vanderbilt University; Estados UnidosFil: Anderson, Lindsay. University of Pretoria. Faculty of Health Sciences; SudáfricaFil: Blidner, Ada Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Tintinger, Gregory R.. University of Pretoria. Faculty of Health Sciences; SudáfricaFil: Anderson, Ronald. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. University of Pretoria. Faculty of Health Sciences; SudáfricaFrontiers Media2021-10-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/163188Rapoport, Bernardo L.; Shannon, Vickie R.; Cooksley, Tim; Johnson, Douglas B.; Anderson, Lindsay; et al.; Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer; Frontiers Media; Frontiers in Pharmacology; 12; 743582; 5-10-2021; 1-171663-9812CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fphar.2021.743582/fullinfo:eu-repo/semantics/altIdentifier/doi/10.3389/fphar.2021.743582info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:12:10Zoai:ri.conicet.gov.ar:11336/163188instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:12:11.124CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer |
title |
Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer |
spellingShingle |
Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer Rapoport, Bernardo L. ANTI-CTLA-4 ANTIBODIES ANTI-PDL-1 MONOCLONAL ANTIBODIES IMMUNE CHECKPOINT INHIBITORS IMMUNE RELATED ADVERSE EFFECTS PNEUMONITIS |
title_short |
Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer |
title_full |
Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer |
title_fullStr |
Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer |
title_full_unstemmed |
Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer |
title_sort |
Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer |
dc.creator.none.fl_str_mv |
Rapoport, Bernardo L. Shannon, Vickie R. Cooksley, Tim Johnson, Douglas B. Anderson, Lindsay Blidner, Ada Gabriela Tintinger, Gregory R. Anderson, Ronald |
author |
Rapoport, Bernardo L. |
author_facet |
Rapoport, Bernardo L. Shannon, Vickie R. Cooksley, Tim Johnson, Douglas B. Anderson, Lindsay Blidner, Ada Gabriela Tintinger, Gregory R. Anderson, Ronald |
author_role |
author |
author2 |
Shannon, Vickie R. Cooksley, Tim Johnson, Douglas B. Anderson, Lindsay Blidner, Ada Gabriela Tintinger, Gregory R. Anderson, Ronald |
author2_role |
author author author author author author author |
dc.subject.none.fl_str_mv |
ANTI-CTLA-4 ANTIBODIES ANTI-PDL-1 MONOCLONAL ANTIBODIES IMMUNE CHECKPOINT INHIBITORS IMMUNE RELATED ADVERSE EFFECTS PNEUMONITIS |
topic |
ANTI-CTLA-4 ANTIBODIES ANTI-PDL-1 MONOCLONAL ANTIBODIES IMMUNE CHECKPOINT INHIBITORS IMMUNE RELATED ADVERSE EFFECTS PNEUMONITIS |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, with agents such as nivolumab, pembrolizumab, and cemiplimab targeting programmed cell death protein-1 (PD-1) and durvalumab, avelumab, and atezolizumab targeting PD-ligand 1 (PD-L1). Ipilimumab targets cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). These inhibitors have shown remarkable efficacy in melanoma, lung cancer, urothelial cancer, and a variety of solid tumors, either as single agents or in combination with other anticancer modalities. Additional indications are continuing to evolve. Checkpoint inhibitors are associated with less toxicity when compared to chemotherapy. These agents enhance the antitumor immune response and produce side- effects known as immune-related adverse events (irAEs). Although the incidence of immune checkpoint inhibitor pneumonitis (ICI-Pneumonitis) is relatively low, this complication is likely to cause the delay or cessation of immunotherapy and, in severe cases, may be associated with treatment-related mortality. The primary mechanism of ICI-Pneumonitis remains unclear, but it is believed to be associated with the immune dysregulation caused by ICIs. The development of irAEs may be related to increased T cell activity against cross-antigens expressed in tumor and normal tissues. Treatment with ICIs is associated with an increased number of activated alveolar T cells and reduced activity of the anti-inflammatory Treg phenotype, leading to dysregulation of T cell activity. This review discusses the pathogenesis of alveolar pneumonitis and the incidence, diagnosis, and clinical management of pulmonary toxicity, as well as the pulmonary complications of ICIs, either as monotherapy or in combination with other anticancer modalities, such as thoracic radiotherapy. Fil: Rapoport, Bernardo L.. University of Pretoria. Faculty of Health Sciences; Sudáfrica. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. The Medical Oncology Centre of Rosebank; Sudáfrica Fil: Shannon, Vickie R.. University of Texas; Estados Unidos Fil: Cooksley, Tim. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. University of Manchester; Reino Unido Fil: Johnson, Douglas B.. Vanderbilt University; Estados Unidos Fil: Anderson, Lindsay. University of Pretoria. Faculty of Health Sciences; Sudáfrica Fil: Blidner, Ada Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Tintinger, Gregory R.. University of Pretoria. Faculty of Health Sciences; Sudáfrica Fil: Anderson, Ronald. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. University of Pretoria. Faculty of Health Sciences; Sudáfrica |
description |
The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, with agents such as nivolumab, pembrolizumab, and cemiplimab targeting programmed cell death protein-1 (PD-1) and durvalumab, avelumab, and atezolizumab targeting PD-ligand 1 (PD-L1). Ipilimumab targets cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). These inhibitors have shown remarkable efficacy in melanoma, lung cancer, urothelial cancer, and a variety of solid tumors, either as single agents or in combination with other anticancer modalities. Additional indications are continuing to evolve. Checkpoint inhibitors are associated with less toxicity when compared to chemotherapy. These agents enhance the antitumor immune response and produce side- effects known as immune-related adverse events (irAEs). Although the incidence of immune checkpoint inhibitor pneumonitis (ICI-Pneumonitis) is relatively low, this complication is likely to cause the delay or cessation of immunotherapy and, in severe cases, may be associated with treatment-related mortality. The primary mechanism of ICI-Pneumonitis remains unclear, but it is believed to be associated with the immune dysregulation caused by ICIs. The development of irAEs may be related to increased T cell activity against cross-antigens expressed in tumor and normal tissues. Treatment with ICIs is associated with an increased number of activated alveolar T cells and reduced activity of the anti-inflammatory Treg phenotype, leading to dysregulation of T cell activity. This review discusses the pathogenesis of alveolar pneumonitis and the incidence, diagnosis, and clinical management of pulmonary toxicity, as well as the pulmonary complications of ICIs, either as monotherapy or in combination with other anticancer modalities, such as thoracic radiotherapy. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-10-05 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/163188 Rapoport, Bernardo L.; Shannon, Vickie R.; Cooksley, Tim; Johnson, Douglas B.; Anderson, Lindsay; et al.; Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer; Frontiers Media; Frontiers in Pharmacology; 12; 743582; 5-10-2021; 1-17 1663-9812 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/163188 |
identifier_str_mv |
Rapoport, Bernardo L.; Shannon, Vickie R.; Cooksley, Tim; Johnson, Douglas B.; Anderson, Lindsay; et al.; Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer; Frontiers Media; Frontiers in Pharmacology; 12; 743582; 5-10-2021; 1-17 1663-9812 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fphar.2021.743582/full info:eu-repo/semantics/altIdentifier/doi/10.3389/fphar.2021.743582 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Frontiers Media |
publisher.none.fl_str_mv |
Frontiers Media |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614026666967040 |
score |
13.070432 |